Richmond, Va.-based drugmaker Kaleo plans to relaunch its epinephrine auto-injector Auvi-Q in the first half of 2017, reports Reuters.
The device was recalled last February due to dosing accuracy concerns. While Paris-based Sanofi had licensed and manufactured Auvi-Q, the company returned the rights to Kaleo after the recall, according to the report.
Once back on the market, Auvi-Q will compete with Mylan's EpiPen, which has a list price of $608 for a pack of two.
Kaleo declined to comment on a list price for Auvi-Q, but CEO Spencer Williamson told Reuters: "We are working on what is the right price to assure that the ultimate patient co-pay is low."
While Auvi-Q delivers the same epinephrine as EpiPen, the device is shaped like a credit card and contains a voice system to prompt users administering the device.
Mr. Williamson said the devices will be manufactured at an automated robotic production line in the Midwest.
More articles on supply chain:
HSCA's 'Total Visibility Project' boosts available product info for GPOs, providers
FDA approved Merck's Keytruda as first line treatment against lung cancer
Supply chain tip of the week: Use evidence-based collaboration to drive clinician engagement